This is a routine executive appointment with no immediate financial impact. Monitor upcoming quarterly results for any operational execution changes under the new President. The hire signals focus on scaling commercial operations, but no guidance or financial data was provided.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $60.60entry
- T+1 · 5mo ago −6.90%α −5.65% · $56.42
- T+5 · 5mo ago −4.16%α −1.93% · $58.08
- T+20 · 4mo ago +3.02%α +2.82% · $62.43
- T+60 · 2mo ago +38.55%α +37.55% · $83.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GeneDx appointed Mark Gardner as President, effective June 15, 2026, to oversee lab and commercial operations. Gardner, a former Quest Diagnostics executive, received a compensation package including a $530,000 base salary, 65% target bonus, and $2,000,000 in restricted stock units. This is a routine executive hire with no financial data or guidance provided.
Key Facts
- Mark Gardner appointed President effective June 15, 2026, reporting to CEO Katherine Stueland
- Gardner previously served as SVP of Molecular Genomics and Oncology at Quest Diagnostics (Sept 2022, June 2026)
- Employment agreement: $530,000 annual base salary, 65% target bonus, $2,000,000 in RSUs vesting over 4 years
- Bryan Dechairo transitions to lead product, technology and innovation initiatives
- No financial results, guidance, or material operational metrics disclosed in the filing
Financial Impact
Compensation package for new President: $530,000 base salary, $344,500 target bonus, $2,000,000 in RSUs
Risk Factors
- No financial data or guidance provided to assess impact on operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-043431 |
| Exhibit: exhibit991-6162026pressrel.htm | 0001628280-26-043431 |
| Document: 0001628280-26-043431-index-headers.html | 0001628280-26-043431 |
| Document: 0001628280-26-043431-index.html | 0001628280-26-043431 |
| Document: 0001628280-26-043431.txt | 0001628280-26-043431 |
Track record
13 reports on WGS
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +63.51% at T+60 after the May 20, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $52.37 Now $51.02 −2.58% settles Feb 11
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $54.83 Now $51.02 −6.95% settles Feb 8
- Nov 6, 202610d ago SC 13G Neutral 3/10 Entry $62.37 Now $51.02 −18.20% settles Feb 4
- Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $97.83 Now $51.02 +47.85% settles Dec 15
- Sep 11, 20269w ago Insider Cluster Neutral 2/10 Entry $89.74 Now $51.02 −43.15% settles Dec 8
- Sep 1, 202610w ago 144 Neutral 2/10 Entry $86.72 Now $51.02 −41.17% settles Nov 27
- Jun 16, 202621w ago 8-K Neutral 3/10 Viewing Entry $60.60 to $83.96 Now $51.02 −15.81% ▲ +38.55% +37.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bullish 4/10 Entry $59.92 to $85.87 Now $51.02 −14.85% ▲ +43.31% +40.04% vs SPY
- Jun 8, 202623w ago Insider Cluster Bullish 6/10 Entry $56.33 to $86.72 Now $51.02 −9.43% ▲ +53.95% +50.14% vs SPY
- May 20, 202625w ago Insider Cluster Bullish 6/10 Entry $47.33 to $77.39 Now $51.02 +7.80% ▲ +63.51% +59.21% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers